Amunix
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.
Versartis
Series D in 2013
Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.